These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 9205773

  • 1. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
    Yamamoto S, Hayashi N, Kometani M, Nakao K, Inukai T.
    Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension.
    Inada Y, Murakami M, Kaido K, Nakao K.
    Arzneimittelforschung; 1999 Jan; 49(1):13-21. PubMed ID: 10028373
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models.
    Yamamoto S, Hayashi N, Kometani M, Nakao K.
    Arzneimittelforschung; 1997 May; 47(5):630-4. PubMed ID: 9205777
    [Abstract] [Full Text] [Related]

  • 7. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction.
    de Gasparo M, Hess P, Nuesslein-Hildesheim B, Bruneval P, Clozel JP.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):151-8. PubMed ID: 11967807
    [Abstract] [Full Text] [Related]

  • 8. Effect of valsartan on angiotensin II- and vasopressin-degrading activities in the kidney of normotensive and hypertensive rats.
    Prieto I, Martínez JM, Hermoso F, Ramírez MJ, de Gasparo M, Vargas F, Alba F, Ramírez M.
    Horm Metab Res; 2001 Sep; 33(9):559-63. PubMed ID: 11561217
    [Abstract] [Full Text] [Related]

  • 9. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects.
    Morgan JM, Palmisano M, Piraino A, Hirschhorn W, Spencer S, Prasad PP, Ortiz M, Lloyd P.
    Clin Pharmacol Ther; 1997 Jan; 61(1):35-44. PubMed ID: 9024172
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs.
    Ueda M, Matsumura S, Masui M, Matsuura E, Kawakami M, Fujitomo H, Umeda T, Kagawa H, Hirohata S, Shima K.
    Arzneimittelforschung; 1993 Dec; 43(12):1282-90. PubMed ID: 8141815
    [Abstract] [Full Text] [Related]

  • 11. Long-term blockade of the angiotensin II receptor in renin transgenic rats, salt-loaded Dahl rats, and stroke-prone spontaneously hypertensive rats.
    Stasch JP, Knorr A, Hirth-Dietrich C, Krämer T, Hübsch W, Dressel J, Fey P, Beuck M, Sander E, Frobel K, Kazda S.
    Arzneimittelforschung; 1997 Sep; 47(9):1016-23. PubMed ID: 9342414
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M, Ménard J, Bissery A, Guyenne TT, Bura-Rivière A, Vaidyanathan S, Camisasca RP.
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [Abstract] [Full Text] [Related]

  • 14. Hypotensive and hemodynamic effects of the new non-sulfhydryl angiotensin converting enzyme inhibitor N-[8-amino-1(S)-carboxyoctyl]-L-alanyl-L-proline.
    Shirota M, Iijima M, Ushijima T, Kajiwara Y, Kitabatake K.
    Arzneimittelforschung; 1990 Dec; 40(12):1303-9. PubMed ID: 2095126
    [Abstract] [Full Text] [Related]

  • 15. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
    Nagata S, Takeyama K, Fukuya F, Nagai R, Hosoki K, Nishimura K, Deguchi T, Karasawa T.
    Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
    Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z.
    Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
    Lacour C, Canals F, Galindo G, Cazaubon C, Segondy D, Nisato D.
    Eur J Pharmacol; 1994 Nov 03; 264(3):307-16. PubMed ID: 7698170
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T, Cheruvu M, Olsufka R, Sandvik ER, Lane CE, Budman J, Hill CM, Klein U, Hegde SS.
    J Cardiovasc Pharmacol; 2011 Apr 03; 57(4):495-504. PubMed ID: 21297495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.